CME Group Inc. (CME), headquartered in Chicago, Illinois, operates contract markets for the trading of futures and options on futures contracts. Valued at $94.3 billion by market cap, the company offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, and more. It facilitates trading on its trading floors, electronic platform, and through privately negotiated transactions that it clears.

Shares of this leading derivatives marketplace have underperformed the broader market over the past year. CME has declined 4.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.2%. In 2026, CME stock is down 3.8%, while SPX is up 13.2% on a YTD basis.

More News from Barchart

• Marvell Technology (MRVL) Stock Might Offer a Quick Bounce Before Earnings

• Most Analysts Still Aren't Bullish on Tesla Stock, Even After Recent Selloff. Here's Why.

Narrowing the focus, CME has also lagged behind the iShares U.S. Broker-Dealers & Securities Exchanges ETF (IAI). The exchange-traded fund has gained about 7.2% over the past year. Moreover, the ETF's 5.6% gains on a YTD basis outshine the stock's losses over the same time frame.

CME Group's underperformance has been driven by a combination of operational cost pressures, competitive threats from alternative products like perpetual futures, and market uncertainty. These headwinds have been compounded by elevated operating expenses from technology investments, softer volumes in core interest rate contracts relative to prior peaks, and persistent insider selling.

On Jul. 22, CME shares closed up by 5% after reporting its Q2 results. Its adjusted EPS of $2.99 exceeded Wall Street expectations of $2.91. The company's revenue was $1.71 billion, exceeding Wall Street forecasts of $1.68 billion.

For the current fiscal year, ending in December, analysts expect CME's EPS to rise 9.6% to $12.27 on a diluted basis. The company's earnings surprise history is mixed. It beat the consensus estimate in three of the last four quarters while missing the forecast on another occasion.

Among the 18 analysts covering CME stock, the consensus is a "Moderate Buy." That's based on six "Strong Buy" ratings, three "Moderate Buys," six "Holds," one "Moderate Sell," and two "Strong Sells."